Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Dexmedetomidine and 5-year Outcome in Elderly Patients After Surgery

20. juni 2019 opdateret af: Dong-Xin Wang, Peking University First Hospital

Impact of Dexmedetomidine on Long-term Outcome in Elderly Patients After Noncardiac Surgery: 5-year Follow-up of a Randomized Controlled Trial

Delirium is a frequent postoperative complication. Its occurrence is associated with worse long-term outcomes. In a previous randomized controlled trial, prophylactic low-dose dexmedetomidine infusion during the early postoperative period decreased the incidence of delirium in elderly patients after surgery. The purpose of this 5-year follow-up study is to evaluate whether prophylactic low-dose dexmedetomidine infusion can improve the 5-year outcomes in elderly patients recruited in the previous randomized controlled trial.

Studieoversigt

Detaljeret beskrivelse

Delirium is a frequent postoperative complication; a systematic review revealed that postoperative delirium occurs in 36.8% of surgical patients, and its prevalence increases with age. The occurrence of delirium is associated with worse long-term outcomes including worse functional recovery, decline in cognitive function, and increased mortality rate. Surgical stress, pain, and sleep disturbances are important factors leading to postoperative delirium in the elderly.

Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist that provides anti-anxiety, sedation, and modest analgesia with minimal respiratory depression. For mechanically ventilated intensive care unit (ICU) patients, dexmedetomidine sedation improves the quality of sleep, decreases the incidence of delirium, and shortens the duration of ICU stay. For patients undergoing surgery, perioperative dexmedetomidine relieves the severity of stress response, decreases the requirement of anesthetics, and improves postoperative analgesia.

In the previous stage of the current study, 700 elderly patients who were admitted to the ICU after noncardiac surgery were recruited and randomized into two groups (dexmedetomidine group and placebo [normal saline] group). The results showed that prophylactic low-dose dexmedetomidine infusion during the early postoperative period ameliorated the subjective sleep quality and decreased the incidence of delirium (22.6% [79/350] with placebo vs. 9.1% [32/350] with dexmedetomidine; odds ratio 0.35, 95% confidence interval 0.22 to 0.54; p < 0.0001). The investigators hypothesize that low-dose dexmedetomidine infusion may also improve long-term outcome in this patient population.

The purpose of this 5-year follow-up study is to evaluate whether prophylactic low-dose dexmedetomidine infusion during the early postoperative period can improve the 5-year outcomes in elderly patients recruited in the previous randomized controlled trial.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

700

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Beijing, Kina, 100034
        • Peking University First Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

65 år til 90 år (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Patients were included if they met all of the following criteria:

  • Age of 65 years or older;
  • Underwent elective noncardiac surgery under general anesthesia;
  • Admitted to ICU after surgery.

Exclusion Criteria:

Patients were excluded if they met any of the following criteria:

  • Preoperative history of schizophrenia, epilepsy, Parkinsonism or myasthenia gravis;
  • Inability to communicate in the preoperative period (because of coma, profound dementia or language barrier);
  • Brain injury or neurosurgery;
  • Preoperative left ventricular ejection fraction < 30%, sick sinus syndrome, severe sinus bradycardia (< 50 beats per minute), or second-degree or greater atrioventricular block without pacemaker;
  • Serious hepatic dysfunction (Child-Pugh class C);
  • Serious renal dysfunction (undergoing dialysis before surgery); or
  • Unlikely to survive for more than 24 hours.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: dexmedetomidin gruppe
Til patienter, der ikke var intuberet, blev dexmedetomidin infunderet med en hastighed på 0,1 mikrogram/kg pr. time fra forsøgsrekruttering på operationsdagen til kl. 8:00 den første dag efter operationen. For patienter, der var intuberet og mekanisk ventileret, blev dexmedetomidininfusion påbegyndt, efter at Richmond Agitation Sedation Scale var -2 eller højere efter indlæggelse på intensivafdeling indtil kl. 8.00 den første dag efter operationen.
lavdosis dexmedetomidininfusion
Andre navne:
  • dexmedetomidinhydrochlorid
Placebo komparator: placebo gruppe
Normalt saltvand blev infunderet med samme hastighed i samme varighed som i placebogruppen.
normal saltvandsinfusion
Andre navne:
  • normalt saltvand
  • 0,9% natriumchlorid

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Duration of 5-year survival after surgery
Tidsramme: From the day of surgery until the end of the 5th year after surgery
Duration of 5-year survival after surgery
From the day of surgery until the end of the 5th year after surgery

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Survival rates after surgery
Tidsramme: At 6 months, 1 year, 2 years ,3 years, 4 years,and 5 years after surgery
Survival rates at different timepoints after surgery
At 6 months, 1 year, 2 years ,3 years, 4 years,and 5 years after surgery
Cognitive function in 5-year survivors after surgery
Tidsramme: At the end of the 5th year after surgery
Cognitive function is assessed with Telephone Interview for Cognitive Status-Modified (TICS-M).
At the end of the 5th year after surgery
Health related quality of life in 5-year survivors after surgery
Tidsramme: At the end of the 5th year after surgery
Health related quality of life is assessed with World Health Organization Quality of Life-BREF (WHOQOL-BREF).
At the end of the 5th year after surgery

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Survival rates in the subgroup of patients after cancer or non-cancer surgery
Tidsramme: At 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years after surgery
Survival rates at different time-points in the subgroup of patients after cancer or non-cancer surgery
At 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years after surgery
Duration of survival in the subgroup of patients after cancer or non-cancer surgery
Tidsramme: From the day of surgery until the end of the 5th year after surgery
Duration of survival in the subgroup of patients after cancer or non-cancer surgery
From the day of surgery until the end of the 5th year after surgery
Cognitive function in the subgroup of 5-year survivors after cancer or non-cancer surgery
Tidsramme: At the end of the 5th year after surgery
Cognitive function is assessed with Telephone Interview for Cognitive Status-Modified (TICS-M)
At the end of the 5th year after surgery
Health related quality of life in the subgroup of 5-year survivors after cancer or non-cancer surgery
Tidsramme: At the end of the 5th year after surgery
Health related quality of life is assessed with World Health Organization Quality of Life-BREF (WHOQOL-BREF).
At the end of the 5th year after surgery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juni 2017

Primær færdiggørelse (Faktiske)

8. januar 2019

Studieafslutning (Faktiske)

1. april 2019

Datoer for studieregistrering

Først indsendt

12. februar 2018

Først indsendt, der opfyldte QC-kriterier

12. februar 2018

Først opslået (Faktiske)

19. februar 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. juni 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. juni 2019

Sidst verificeret

1. juni 2019

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Data will be provided on request.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Delirium

Kliniske forsøg med dexmedetomidin

3
Abonner